AstraZeneca Secures US, EU Nod for New Myasthenia Gravis Drug Klygefa
AstraZeneca (AZN) received FDA and EU approvals for Klygefa, a new treatment for generalized myasthenia gravis (gMG). The drug showed significant improvements in daily activities in a phase III study. AZN estimates 98,500 gMG cases in the US and 82,500 in five major European countries. Klygefa expands AZN's gMG portfolio, offering a convenient, self-administered option. Competitors include UCB's Zilbrysq and other treatments with different mechanisms.
How this was made

The 30-second read
Why it matters
The approvals add a once-weekly, self-administered subcutaneous option to AstraZeneca’s gMG portfolio, potentially improving patient adherence and access while raising cannibalization risk versus Soliris and Ultomiris. Boxed warning and US REMS may limit ease of prescribing and uptake.
Market read
This is a direct regulatory catalyst for AZN tied to a new gMG therapy, with explicit discussion of dosing convenience, cannibalization risk, and competitive positioning.
What to watch
The article does not quantify expected uptake, pricing, or reimbursement dynamics, which could dominate near-term revenue impact despite the approval headline.
Background
Klygefa is a complement C5 inhibitor for adults with generalized myasthenia gravis who are anti-AChR antibody-positive, with US approval for monotherapy population and EU approval as add-on to standard therapy.
Ticker impact
AstraZeneca received FDA and EU approvals for Klygefa (gefurulimab) for AChR-positive generalized myasthenia gravis, supported by Phase 3 PREVAIL results.
Likely positive bias as the market prices in incremental gMG revenue and differentiated administration, partially offset by cannibalization risk versus Soliris/Ultomiris.
The article is a first-disclosure of US and EU approvals and highlights differentiated SC autoinjector convenience, while explicitly flagging potential cannibalization and boxed-warning/REMS constraints.
Market effects
Reinforces competitive intensity in the gMG complement C5-inhibitor class, with administration convenience becoming a key differentiator.
US and EU label expansion broadens addressable market for gMG therapies and may shift prescribing patterns across both regions.
Could influence global payer and formulary decisions for complement inhibition in gMG, even beyond the US/EU label scope.
Counterpoint
Klygefa’s convenience advantage may not translate into net share gains if REMS burden, safety monitoring, and payer preferences keep patients on established IV regimens.
Key entities
- companyAstraZeneca
Secured FDA and EU approvals for Klygefa (gefurulimab) for AChR-positive gMG, supported by Phase 3 PREVAIL.
- drugKlygefa (gefurulimab)
Once-weekly subcutaneous complement C5 inhibitor for AChR-positive generalized myasthenia gravis.
- clinical_trialPREVAIL study
Phase 3 trial cited as showing significant improvement in daily activity ability versus placebo at 26 weeks.
- drugSoliris
AstraZeneca’s IV complement C5 inhibitor for gMG, administered every two weeks.
- drugUltomiris
AstraZeneca’s IV complement C5 inhibitor for gMG, requiring maintenance infusions every eight weeks.



